Recent Updates
Recently added Catalysts
IPHA Positive Sentiment

Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Key Takeaway: Innate Pharma showcased initial Phase 1 clinical data for IPH4502 at the ENA 2026 conference. The data indicates positive early results, contributing to the ongoing development of this therapeutic candidate. This presentation marks a significant step in the drug's clinical evaluation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innate Pharma presented initial data for IPH4502.
  • The presentation occurred at ENA 2026.
  • Phase 1 clinical data shows promising results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7%
average across 4 past catalysts
Lead asset
IPH5201
Phase 2 · Non Small Cell Lung Cancer

Full Press Release Details

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Innate Pharma presents initial Phase 1 clinical data for IPH4502 at ENA 2026

Frequently Asked Questions

What is IPH4502?

IPH4502 is a therapeutic candidate developed by Innate Pharma.

Where was the data presented?

The initial Phase 1 data was presented at ENA 2026.

What phase is IPH4502 currently in?

IPH4502 is currently in Phase 1 clinical trials.

What were the results of the Phase 1 data?

The Phase 1 data showed promising initial results.

Last updated: Nov 18, 2026